KRASG12C inhibitors are commonly used to suppress disease progression in KRASG12C-mutant advanced colorectal cancers (CRC) and pancreatic ductal adenocarcinomas (PDAC), but these treatments can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes. A recent study has examined the genetic landscape of resistance alterations linked to KRAS targeting in KRASG12C-mutant CRC and PDAC. ...
Pancreatic
Advertisement
Challenges in designing and conducting clinical trials for patients with metastatic pancreatic ductal cancer are discussed.
The efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies.
The KRAS G12R mutation is analyzed against other alterations in pancreatic adenocarcinoma, and research findings are shared.
Dr. Strosberg focuses on how previous exposure to alkylating agents can influence tumor biology or immune response.
Dr. Pant shared updates on a phase 1b dose escalation trial of gemcitabine, nab-paclitaxel, and lixumistat.
Dr. Shirakawa highlighted the results of the NAPOLEON-2 trial, including how RWD compare to clinical trial findings.
Dr. Dotan shared the effects of baseline geriatric and QOL assessments on outcomes for older patients with pancreatic cancer.
Dr. Abdelrahim details the impact of UGT1A1*28 polymorphism on tolerability in patients with mPDAC in the NAPOLI 3 study.
Results of NIR-B trial sheds light on the clinical utility of niraparib in patients with BRCA-mutated GI cancers.
A novel auto-segmentation model and radiomics signature may help with preoperative clinical decision-making for GEP-NETs.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.